AR and prostate carcinoma: Some early reports described radiobrominated and radioiodinated androgens for imaging AR in prostate cancer, but their AR binding was poor or not characterized, they were chemically or metabolically unstable, or they did not show clear evidence of AR-selective uptake in rodent prostate [102,103,104,105].